conserved among F. nucleatum but is absent in non-oral Fusobacterium spp (15) . FadA binds vascular endothelial (VE)-cadherin on endothelial cells, causing increased endothelial cell permeability thus allowing bacteria to penetrate through, a likely mechanisms used by F. nucleatum for systemic dissemination (14) .
In the current study, we showed that F. nucleatum binds and invades both normal and cancerous epithelial cells via FadA binding to E-cadherin. This binding leads to growth stimulation of human CRC cells but not the non-cancerous cells. FadA binding to E-cadherin on CRC cells causes nucleus translocation of b-catenin, thus activating b-catenin-regulated transcription (CRT), including increased expression of transcription factors LEF/TCF, oncogenes cyclin D1 and c-Myc, Wnt signaling genes Wnt 7a, 7b and 9a, and inflammatory genes NF-kappa B, IL-6, 8 and 18, all of which are hallmarks of carcinogenesis. Interestingly, although all these tumorigenic responses are activated by FadA through b-catenin, they are differentially regulated because the clathrin inhibitor, Pitstop 2, which inhibits F. nucleatum invasion but not its binding to the CRC cells, only inhibited the inflammatory responses such as NF-kappa B, IL-6, 8 and 18, but did not affect activation of the oncogenes or the Wnt signaling. Thus, activation of the inflammatory responses is invasion dependent, while activation of the oncogenes and Wnt signaling is not. A model of how FadA stimulates tumorigenesis is depicted in Fig. 1 .
The FadA binding site on E-cadherin has been mapped to an 11-amino acid domain. A synthetic peptide corresponding to this domain prevents F. nucleatum from binding and invasion of CRC cells and blocked the activation of oncogenes, Wnt signaling and inflammatory responses (Fig. 1 ). It also inhibits F. nucleatum-driven CRC growth both in vitro and in xenograft mice.
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Translocation of β β-catenin to nuclei (invasion dependent) (invasion independent) The fadA gene levels are significantly increased in the adenoma and carcinoma tissues, compared to the normal controls. The increase is step-wise, from normal controls to the precancerous state (including benign polyps and tissues surrounding the benign and malignant polyps), and from the precancerous state to carcinoma, with an average of 10-fold increase between each step. Furthermore, FadA transcription in F. nucleatum in the carcinoma tissue is significantly increased compared to that in the normal controls and the precancerous tissues, indicating an increase virulence activity of F. nucleatum in CRC. The increased FadA expression correlates with increased tumorigenesis responses in the carcinomas.
In a separate study, F. nucleatum was shown to induce tumor multiplicity and selectively recruit tumor-infiltrating myeloid cells to promote tumorigenesis in APC þ/À mice. Fusobacterium spp were found to be enriched in adenomas and stools from adenoma and carcinoma patients (20) . Together, these studies demonstrate that F. nucleatum stimulates colorectal carcinogenesis.
Future Directions
The discovery of an oral commensal, F. nucleatum, as a microbial driver of CRC provides a brand new perspective on the etiology, mechanism, diagnosis, treatment and prevention of this debilitating disease. The mechanistic studies identified novel diagnostic and therapeutic targets. Because it is unique to F. nucleatum, fadA may be an ideal diagnostic marker for early detection of CRC. Diagnostic criteria may be developed to define healthy, precancerous, and cancerous states according to the fadA gene levels. The inhibitory peptide and/or its derivatives may be used in precision medicine to specifically eradicate F. nucleatum to reduce CRC risk, similar to eradicating H. pylori to reduce gastric cancer risk. Compared to antibiotic therapies, the precision elimination avoids disturbance of the flora. The potential use of FadA in disease diagnosis, treatment and prevention warrants further testing.
Elucidation of the role of F. nucleatum in CRC sheds new light on the role of oral microbiome in human health. F. nucleatum is abundantly present in the oral cavity and increases in the presence of periodontal disease. Incidentally, both periodontal disease and CRC are considered "old people's diseases," with their risks increasing with age. Several questions thus arise: Is periodontal disease a risk factor for CRC? Given the connectivity of the digestive tract, could F. nucleatum or other oral bacteria be involved in additional GI disorders? Furthermore, based on the "mobility" of F. nucleatum and the omnipresence of cadherins, could this organism be involved in cancers beyond the GI tract? Answers to these questions will shed new lights on the role of oral microbiome in human health.
